Skip to content

Comprehensive Review of Retinal Pseudo-Holes: Clinical Presentation, Diagnosis, Pathophysiology, and Management

Clinical Presentation, Diagnostic Approaches, Pathophysiology, and Management of Retinal Pseudo-Holes: a Comprehensive Synthesis of 35 Peer-Reviewed Studies

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06800638
Enrollment
10
Registered
2025-01-30
Start date
2024-06-01
Completion date
2024-09-25
Last updated
2025-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related Disease, Epiretinal Membrane, Idiopathic ERM

Brief summary

Retinal pseudo-holes (RPH) are macular abnormalities that mimic macular holes (MH) but lack full-thickness retinal disruption. This systematic review, based on 35 studies, explores their clinical presentation, diagnosis, pathophysiology, and management. Diagnosis: Differentiating RPH from MH is challenging due to overlapping symptoms such as central scotomas and visual distortion. Optical coherence tomography (OCT) has become the gold standard for diagnosis, surpassing older imaging techniques like fundus photography and fluorescein angiography. OCT provides detailed, non-invasive imaging that helps identify RPH's hallmark feature: a foveal depression without retinal break. Pathophysiology: RPH is primarily caused by mechanical forces exerted on the macula by epiretinal membranes (ERM) and vitreomacular traction (VMT). These forces distort the retina, creating a pseudo-hole. Risk factors include aging, high myopia, trauma, and diabetes. Management: Many RPH cases are managed conservatively with regular monitoring, as the condition often remains stable. Surgical intervention, such as pars plana vitrectomy (PPV) with membrane peeling, is reserved for symptomatic cases with significant visual impairment. Surgery has shown promising outcomes, with most patients experiencing improved visual acuity. Research Needs: Further studies are needed to explore the long-term outcomes of RPH, identify factors predicting progression to MH, and assess the utility of advanced imaging techniques like OCT angiography in improving diagnosis and monitoring. This review underscores the importance of accurate differentiation between RPH and MH to ensure appropriate management and avoid unnecessary treatments.

Detailed description

This is a REVIEW study on Retinal pseudo-holes.

Interventions

None listed

Sponsors

Mohammad Reza Tokhmehchi
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Studies that directly addressed retinal pseudo-holes, their clinical presentation, diagnostic modalities, pathophysiology, or treatment. * Peer-reviewed clinical trials, case reports, observational studies, and reviews. * Studies that utilized OCT or other imaging techniques (such as fluorescein angiography or fundus photography) to diagnose retinal pseudo-holes. * Studies that were published in English and provided full-text access.

Exclusion criteria

* Studies that did not specifically focus on retinal pseudo-holes but instead dealt with other retinal conditions (e.g., full-thickness macular holes, retinal detachment). * Studies that were not peer-reviewed (e.g., conference abstracts, opinion pieces). * Non-English language studies or those without available full texts.

Design outcomes

Primary

MeasureTime frameDescription
Retinal Thicknessup to 12 weeksMeasuring retinal thickness using Optical Coherence Tomography (OCT) to assess structural changes associated with the severity of the epiretinal membrane. Unit of Measure: Micrometers (µm)

Secondary

MeasureTime frameDescription
Visual Acuityup to 10weeksEvaluating patients' visual acuity using the LogMAR scale to determine the functional impact of the epiretinal membrane on vision. Unit of Measure: LogMAR (logarithm of the minimum angle of resolution)

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026